Join us at AACR Annual Meeting 2026

April 17-22, 2026 • San Diego, CA

THE PREMIER EVENT IN CANCER RESEARCH:

Precision Therapies • Cancer Biology • Translational Studies • Clinical Trials • Survivorship • Advocacy

WHAT TO EXPECT AT THE EVENT:

The AACR Annual Meeting 2026 is a central gathering for the global cancer research community, bringing together scientists, clinicians, patients, survivors, and advocates to share the latest advances in oncology. 

We look forward to engaging with leaders across cancer biology, translational research, and clinical studies, and to learning from work that spans population science, prevention, survivorship, and advocacy. 

Each year, the AACR Annual Meeting showcases groundbreaking research from leading institutions around the world, highlighting the collective progress shaping the future of cancer care.

MEET US AT BOOTH #4415:

For more than two decades, we have partnered with oncology innovators to generate rigorous, decision-ready data across their preclinical journey. 

Our integrated oncology capabilities span advanced in vitro and in vivo platforms, clinically relevant models, and end-to-end preclinical services designed to support confident, faster program decisions.

Connect with Bindiya Patel, Mariam Assadian, and Yinfei Yin from ChemPartner’s Business Development team to discuss how our collaborative, scientist-led approach can support your oncology programs - from early discovery through IND-enabling studies.

EXPLORE OUR NEW ONCOLOGY POSTERS!

Don’t forget to stop by our posters to learn about our latest programs and innovations from our stellar scientists: Bing Li, Qikuan Chen, Greg Liang, and Yuzhou Xu.

• “In vitro and in vivo study of C2LP-ADC & CLP2-ADC targeting human breast and gastric cancer”

• “Development and Characterization of A Novel In Vivo JIMT-1 DS8201a Resistant Models and Its Efficacy Evaluation”

• “Characterization and Preclinical Efficacy of a CD3×CD20 Bispecific T Cell Engager in a Humanized PBMC Mouse Model”

• “Engineering Multi-Specific and Multi-Payload ADCs to Address Tumor Heterogeneity and Drug Resistance”

• “Evaluation of Targeted Protein Degraders Using High-Throughput Ubiquitination Assays for Mechanistic and SAR Analysis”

• “Modeling of Acquired Resistance to the multi-RAS inhibitor RMC6236 in KRAS Mutant Pancreatic Ductal Adenocarcinoma”